Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Perceptive Advisors invests $100mm in Athenex through stock and debt agreement

Executive Summary

Perceptive Advisors invested $100mm in cancer therapeutics developer Athenex Inc. The firm purchased 2.68mm common shares at $18.66 (a slight discount) for gross proceeds to Athenex of $50mm, and also entered into a $50mm senior secured loan facility. (The loan matures in five years and carries interest at a floating annual rate equal to LIBOR (with a 2% floor) plus 9%.) Proceeds will support drug development activities. Concurrently, Athenex announced the creation of a joint venture with Xiangxue Life Sciences, and the in-licensing of a pegylated human arginase from PolyTom, a division of Avalon Biomedical.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Investment in Public Equity
    • Private Placement

Related Companies